Trastuzumab emtansine (T-DM1)-associated cardiotoxicity: Pooled analysis in advanced HER2-positive breast cancer

T-DM1 has been approved for the treatment of HER2+ breast cancer. Cardiac dysfunction is a side effect of trastuzumab, a component of T-DM1. However, little is known about T-DM1-associated cardiotoxicity.

Source: European Journal of Cancer - January 12, 2020 Category: Cancer & Oncology Authors: Noam Pond é, Lieveke Ameye, Matteo Lambertini, Marianne Paesmans, Martine Piccart, Evandro de Azambuja Tags: Original Research Source Type: research